| 伊立替康联合替莫唑胺对儿童难治性实体瘤近期疗效的研究 |
| |
| 引用本文： | 司绍永,仲任,孙立荣,徐慧娟,李学荣,庞秀英. 伊立替康联合替莫唑胺对儿童难治性实体瘤近期疗效的研究[J]. 现代生物医学进展, 2011, 11(15): 2948-2951 |
| |
| 作者姓名： | 司绍永 仲任 孙立荣 徐慧娟 李学荣 庞秀英 |
| |
| 作者单位： | 青岛大学医学院附属医院小儿血液科,山东青岛,266003 |
| |
| 摘 要： | 目的:研究伊立替康(Irinotecan,CPT-11)联合替莫唑胺(Temozolomide,TMZ)对儿童难治性实体瘤的近期疗效;方法:选取了11名难治性儿童实体瘤患者并争取了家属同意,分别给予了伊立替康:60mg/m~2/d,ivgtt,连用5天;替莫唑胺:75mg/m~2/d,连用5天,在伊立替康前一小时口服;用药期间同时给予思密达或者头孢菌素类抗生素预防药物相关性腹泻,并定期复查血象以及肝肾功;28天一疗程,每疗程行复查CT或MRI进行疗效评定和药物安全性评价。结果:11例患者经过2-6个疗程的治疗;疾病控制率(DCR)达到54%;明显延长了患者的无疾病进展生存期,中位无疾病进展生存期3.3个月。用药期间不良事件主要包括0-Ⅲ级的药物相关性腹泻、呕吐、血小板减少、贫血等;结论:伊立替康联合替莫唑胺方案能明显延长儿童难治实体瘤患者未进展存活时间,且耐受性好、安全性高,可以作为儿童晚期实体瘤患者的首选治疗方案。
|
| 关 键 词： | 伊立替康 替莫唑胺 实体瘤 |
Irinotecan Plus Temozolomide for Relapsed or Refractory Pediatric Solid Tumor |
| |
| SI Shao-yong,ZHONG Ren,SUN Li-rong,XU Hui-juan,LI Xue-rong,PANG Xiu-ying. Irinotecan Plus Temozolomide for Relapsed or Refractory Pediatric Solid Tumor[J]. Progress in Modern Biomedicine, 2011, 11(15): 2948-2951 |
| |
| Authors: | SI Shao-yong ZHONG Ren SUN Li-rong XU Hui-juan LI Xue-rong PANG Xiu-ying |
| |
| Affiliation: | (Department of Pediatric Hematology,Qingdao University Medical College,Affiliated Hospital,Qingdao,Shandong Province, China,266003) |
| |
| Abstract: | Objective:To analyze the lately therapeutic effect of Irinotecan combined Temozolomide in children with recurrent/ resistant solid tumor.Methods:A total of 11 patients received oral temozolomide 75mg/m~2/d on days 1 through 5 combined with intravenous Irinotecan 60mg/m~2/d on days 1 to 5 in 3 weeks courses.Daily oral cefaclor was used to reduce irinotecan -associated diarrhea. Meantime,clinical experience and contrast enhanced CT or MRI scan were performed every course.Results:All the patients received two ... |
| |
| Keywords: | Irinotecan Temozolomide Solid tumor |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
